• The9’s investee Nanyang Biologics moved closer to a Nasdaq listing via a planned business combination with RF Acquisition Corp II.
• On Aug. 19, 2026, RFAI shareholders backed the deal, clearing a key step toward trading under ticker “NYB.”
• The9 expects to own about 15% to 16% of the combined Nasdaq-listed company once the transaction closes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The9 Limited published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.